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Abstract
Background: The kava-kava plant (Piper methysticum) is traditionally consumed by the pacific islanders and has
been linked to be involved in several biological activities. Flavokawain B is a unique chalcone, which can be found
in the roots of the kava-kava plant. In this study, the operational mechanism of the anti-cancer activity of a synthetic
Flavokawain B (FKB) on two breast cancer cell lines, MCF-7 and MDA-MB231 was investigated.
Method: Several in vitro assays were attempted such as MTT, flow cytometry of cell cycle analysis, annexin V analysis,
and JC-1 analysis to detect apoptosis. Moreover, in vitro metastasis assays were also performed such as transwell
migration assay, invasion assay, rat aorta ring and HUVEC tube formation. Molecular analysis of related genes and
proteins were conducted using real-time PCR and proteome profiler analysis.
Results: Based on our results, apoptosis was induced when both MCF-7 and MDA-MB231 were treated with FKB.
A significant G2/M arrest was seen in MDA-MB231 cells. Additionally, FKB also inhibited the in vitro migration and
invasion in MDA-MB231 cells in a dose dependent manner. Moreover, FKB can be a potential inhibitor in angiogenesis
as it suppressed the formation of vessels in HUVEC cells as well as in the ex-vivo rat aortic ring assay.
Conclusion: Our findings suggested that FKB also regulated several receptor tyrosine kinases. Overall, FKB is not only a
potential candidate to be an anti-cancer agent, but as an anti-metastatic agent as well.
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Background
Cancer is still a worrying disease despite the progressive
scientific research conducted. In fact, breast cancer still
remains one of the most deadliest cancer among women
[1]. Approximately around 1 out of 8 women will de-
velop breast cancer at some point in their lives [1].
According to the cancer statistics reported, around 14 %
of breast-cancer related cases ended up being fatal [1].
Additionally, breast cancer has a tendency to become
malignant [1]. More than half of the patients diagnosed
with breast cancer have already developed metastatic
breast cancer [2]. Metastasis is usually the main cause of
cancer-related deaths [2, 3]. Therefore, it is extremely
crucial to not only treat, but also prevent this disease
from becoming malignant. Natural-derived drugs have
become a more favourable option in the pharmaceutical
industry [4, 5]. In fact, in the development of new anti-
cancer drugs, natural products still remain as one of the
major players in providing the database [6].
The kava-kava plant extract has been used as traditional
remedies to treat various illnesses [7]. Interestingly, there
has been a correlation between the consumption of the
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kava extracts with the incidence of cancer [8]. Some of
the most interesting components that can be found
from the kava root extracts include the flavokawains
[9]. There are three types of flavokawains that can be
found and the differences lies in the side chain [10].
Flavokawain B has gained worldwide interest due to its
promising anti-cancer activity as reported by several
studies [11, 12]. This chalcone was reported to be
present in two other types of plant species; the alpinia
and piper family [9, 13]. Flavokawain B was found to
possess several fascinating biological activities such as,
anti-inflammatory, antinociceptive and anti-cancer ac-
tivities [13, 14].
The fact that receptor tyrosine kinases (RTK) play an
important role in cancer progression was an impactful dis-
covery [15]. There are various RTKs and downstream pro-
teins involved in breast cancer and metastasis such as
VEGF, MMP9, GLUT1 and FOXM1. Flavonoids have
been reported to regulate some of these RTKs and thus
have the potential to become promising anti-cancer
agents. Nevertheless, to the best of our knowledge, studies
on the effects of flavokawain B on breast cancer cells in
vitro and on the RTKs have not yet been reported. There-
fore, this study aims to elucidate the anti-metastatic effects
of flavokawain B on breast cancer cells in vitro.
Results
Flavokawain B inhibited the proliferation of MCF-7 and
MDA-MB231 in vitro
MTT analysis was performed to analyze the cytotoxic
effects of flavokawain B on two breast cancer cell lines,
MCF-7 and MDA-MB231, as well as on the non-
transformed mammary epithelial cell line, MCF-10A.
The cells were treated with 7 different concentrations of
flavokawain B for 72 h. As in Fig. 1a, the half-inhibitory
concentration (IC50) of flavokawain B on MDA-MB231
(12.3 μM) was much lower compared to MCF-7
(33.8 μM). Nonetheless, the IC50 of flavokawain B on the
positive control cell line, MCF-10A was considerably
higher than the two cancer cell lines. The BrdU incorp-
oration assay was also conducted to analyze the anti-
proliferative effects of flavokawain B. Fig. 1b depicts that
the percentage of BrdU incorporation is negatively cor-
related with the dose of flavokawain B. Flavokawain B
impeded the proliferation of both MCF-7 and MDA-
MB231 in a dose-dependent manner.
Flavokawain B induced G2/M arrest and apoptosis in
MDA-MB231 and MCF-7
To investigate the effects of flavokawain B on the cell
cycle progression in MDA-MB231 and MCF-7, the
FACS cell cycle analysis was performed. Three different
concentrations of flavokawain B were used as treatment
and the cells were analysed at 12 h and 24 h post-
treatment. Based on Fig. 2 the changes in the G2/M
phase in MDA-MB231 cells were significant as the dose
increases. After 24 h, the percentage of cells in the sub
G0/G1 phase also increased as the dose escalates. In
MCF-7 cells however, there was no significant G2/M
arrest seen at both time points, as depicted in Fig. 2a
(Additional file 1: Figure S1).
One paramater of apoptosis was examined by detect-
ing the externalization of phosphatidylserine. The cells
were stained with Annexin V-FITC and Propidium Iod-
ide before being subjected to flow cytometry. According
to Fig. 2b (Additional file 2: Figure S2), in both MCF-7
and MDA-MB231 a pattern can be seen where there is a
shift in the percentage of cells from viable to early apop-
tosis and to late apoptosis/necrosis as the dose escalates.
Flavokawain B inhibited migration and invasion in vitro
and suppressed the formation of tube-like vessels in vitro
and ex vivo
For the in vitro motility assessment, the scratch (wound
healing) assay was used in MDA-MB231. The percent-
age of wound closure was compared between all treat-
ments of group with the control as showed in Fig. 3a. In
the control group of the MDA-MB231 cells, the area of
the wound was completely covered with migrated cells
after 24 h (100 ± 0.1 %). In the treated groups, the per-
centage of wound closure is negatively correlated to the
dose of flavokawain B given. For the IC12.5, IC50 and
IC75treated groups, the wound closure is approximately
65 ± 4.9, 28.6 ± 5.6 and 5.4 ± 2.7 % respectively.
The transwell assay was also performed to investigate
the effects of flavokawain B on the motility and invasive-
ness of MDA-MB231. The percentage of migrated cells
was inversely proportional to the dose of flavokawain B
according to Fig. 3b. In MDA-MB231 treated cells, the
higher the dose of flavokawain B; the lower the percent-
age of migrated cells through the transwell. For the IC50
treated group, the percentage of migrated cells in MDA-
MB231 was 15.4 %. The matrigel-transwell assay was
conducted using MDA-MB231 cells only since it is
highly invasive as compared to MCF-7. Similar to the in
vitro migration assay, as well as the wound-healing
assay, the percentage of invaded cells is negatively corre-
lated to the dose of flavokawain B. In the flavokawain B-
treated groups, IC12.5, IC25 and IC75 the percentage of
invaded cells were 54.1, 24.7 and 15.5 % correspondingly
as in Fig. 3c.
For the in vitro angiogenesis assessment, the HUVEC
tube formation assay was conducted, followed by treat-
ment with three different concentrations of flavokawain
B. In the IC12.5 treated group, there was no significant
inhibition in the formation of tube-like vessels as repre-
sented in Fig. 4a. The percentage of tube formation in
IC25-treated group was significantly suppressed with
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23.6 % tube formation. There was a total inhibition in
the formation of tube in the IC50-treated group. The ex-
vivo rat aortic ring assay was also conducted to further
understand the anti-angiogenic potential of flavokawain
B as shown in Fig. 4b. This also suggests that flavoka-
wain B regulates angiogenesis in a dose-dependent
manner.
Flavokawain B regulated several metastasis-related pro-
teins and genes, and tyrosine kinases in MDA-MB231
To measure the relative mRNA level of metastasis-related
genes, quantitative real-time analysis was performed as
displayed in Fig. 5. Upon induction with three doses of fla-
vokawain B, the mRNA expression of all genes in MDA-
MB231 treated cells; MMP9, VEGF, GLUT1 and FOXM1
were down regulated. The significance of these findings
were dose-dependent; the lower the dose of flavokawain
B given, the less significant the expression of mRNA.
The expressions of the mRNA level were considered
significant if it were more than 2-fold. In the western
blot analysis on the other hand, the protein expression
of inflammation-related proteins such as NF-KB and
COX-2 were decreased in a dose-dependent manner.
Likewise, the same pattern can be seen in other
metastasis-related proteins such as VEGF, SNAIL and
CXCR4 according to Fig. 5.
Based on the proteome profiler analysis, flavokawain
B regulated several important tyrosine kinases in MDA-
MB231. In Fig. 6, in MDA-MB231, flavokawain B up-
regulated the phosphorylation of p-p38 alpha, p-CREB,
Fig. 1 a Percentage of viability of three cell lines (MCF-7, MDA-MB231 and MCF-10a) when treated with seven doses of flavokawain B measured
through the MTT assay after 72 h. b Percentage of BrdU incorporation in both MCF-7 and MDA-MB231 upon treatment with three different concentrations
of flavokawain B for 48 h. All data are expressed as mean ± S.E.M with three biological replicates
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p-HSP27, p-JNK, p-AKT, p-ERK, p-HSP60, p-WNK1,
p-c-Jun and p-p53.
Discussion
From our findings, it can be suggested that FKB induces
apoptosis and inhibits proliferation in both MCF-7 and
MDA-MB231 cells in vitro as well as halting some of the
steps in the metastatic cascade in MDA-MB231 cells in
vitro. FKB possess anti-proliferative effects and is select-
ive in its actions as evidenced by the MTT and BrdU as-
says. It has been documented in some studies that FKB
induced G2/M arrest in several cancer cell lines [12–14].
It is observed that FKB induced G2/M arrest in MDA-
MB231 cells in the early stages of treatment. Metastasis
accounts for the major cause of cancer-related mortal-
ities especially in breast cancer patients [16]. Therefore
it is essential to not only inhibit the growth of cancer
cells, but hamper the metastatic process as well. The
ability of cancer cells to migrate and invade extracellular
tissues contributes greatly to the likelihood of forming
secondary tumors. Both migration and invasion are cru-
cial steps in metastasis and FKB was shown to impede
both of these processes in vitro dose-dependently. Besides
that, angiogenesis, the formation of blood vessels, is also
an essential step in metastasis because the formation of
secondary tumors is highly dependent on the adequacy of
blood and nutrient supply [17]. FKB was not only able to
impede the motility and invasiveness of MDA-MB231 in
vitro, but also thwart the formation of vessel-like struc-
tures in vitro and ex vivo.To further understand the role
of FKB in suppressing metastasis, the expression of 4
metastasis-related genes were measured in FKB-treated
cells. MMP9 is a matrix metalloproteinase protein that is
actively involved in metastasis, especially relating to angio-
genesis [18, 19]. In breast cancer particularly, MMP9 has
been found to be expressed in tumors expanding to sec-
ondary sites [20]. The down regulation of MMP9 could
decrease the metastatic ability of cancer cells. Apart from
that, cancer cells have a high demand of energy and in-
creased metabolism; therefore the need of substantial en-
ergy is required [21]. The Warburg effect is a popular
doctrine regarding the active level of aerobic glycolysis in
cancer cells [22]. GLUT1 is a glucose transporter that
plays an important role in the uptake of glucose by gly-
colysis in tumor and is often associated in malignant phe-
notypes of cancer [22]. In FKB-treated cells, the
expression of GLUT1 at the mRNA level is decreased in
both cell lines. One of the most infamous biomarkers used
to detect metastasis is VEGF. Most often, VEGF is overex-
pressed in tumors as it promotes angiogenesis as well as
accelerating metastasis [23]. Moreover, FOXM1 is a tran-
scription factor involving in cell cycle progression [24].
Nevertheless, it has been noted that FOXM1 also plays a
role in the development of cancer on a wider scale [25].
FOXM1 has been found to promote metastasis in associ-
ation with MMP9 as well as VEGF [24]. In FKB-treated
cells, it can be seen that FOXM1 was down regulated in
all treated groups in a dose-dependent manner.
Cancer progression as well as the metastatic process
itself is often associated with inflammation [26, 27]. In
fact, it has been put forward that inflammation actually
accelerates the metastasis process altogether [27]. NF-
KB is a well-known protein to be involved in inflamma-
tion and cancer. In fact, through the inhibition of NF-
KB in a breast cancer model, the EMT process, a subset
in the whole metastatic cascade, is decreased [28]. From
our results, it can be suggested that FKB decreases the
protein expression of NF-KB depending on the dose
given. This overall implies that FKB may inhibit the
inflammatory process in cancer cells, and eventually
metastasis. Additionally, FKB was also found to impede
the expression of COX-2, another inflammation-related
protein. In breast cancer specifically, the suppression of
COX-2 has been a targeted therapeutic approach in
treating this disease [29, 30]. As seen in FKB-treated
cells, similar to the expression of NF-KB, there was a
decrement in the level of expression in COX-2 as well.
There are several key regulators in the EMT process in-
cluding E-cadherin, Snail, Slug and Twist [31]. In fact,
the pro-inflammatory protein, NF-KB is also commonly
associated with the activation of EMT; NF-KB is
involved in EMT by regulating and stabilizing the
protein Snail. It has been studied by the depletion of
Snail; the manifestation of metastasis is reduced both
in vitro and in vivo [31]. Moreover, breast cancer is
regularly known to metastasize to the bones, lymph
nodes and lungs. One of the major important players
in this process is the CXCR4 [32]. CXC-chemokine
receptor 4 (CXCR4) belongs to the G-protein coupled
receptor group and is regularly involved in breast
cancer metastasis [32].
Tyrosine kinases play major roles in the apoptosis and
metastasis pathways. Based on the proteome profiler re-
sults in MDA-MB231, the phosphorylation of p38alpha
(See figure on previous page.)
Fig. 2 a Histogram cell cycle analysis of MCF-7 and MDA-MB231 after 12 h and 24 h of treatment with three different doses of flavokawain B. b
Representative histogram analysis of the Annexin V-FITC/PI apoptosis assay via FACS Calibur. Both MCF-7 and MDA-MB231 were treated with three different
concentrations of flavokawain B for 48 h. (Quantitative analyses of cell cycle and annexin V assays are presented in Additional files 1 and 2: Figures S1 and
S2 respectively. All data are expressed as mean ± S.E.M with three biological replicates)
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increased in the FKB-treated group. P38 mitogen-
activated protein kinase is regularly involved in cell pro-
liferation, survival and differentiation [33]. Additionally
the phosphorylation of p38 MAPK is known to lead to
the activation of several other important molecules
including heat shock protein 27 [34]. HSP27 was signifi-
cantly up regulated in the FKB-treated cells. This heat
shock protein is activated by several other factors includ-
ing TNF-alpha, interleukins and growth factors [34].
HSP27 has dual roles in cancer progression, it has been
Fig. 4 a Tube formation analysis of HUVEC cells when treated with three different doses of flavokawain B for 18 h. Experiment was done in
triplicates and all data are expressed as mean ± S.E.M. Magnification: 20X. b Sprouting of vessels from the ex-vivo rat aortic ring assay following
the treatment of three different doses of flavokawain B. The aortas were excised from Sprague-drawley rats and the aorta was incubated for
7 days. Experiment was done in triplicates and all data are expressed as mean ± S.E.M. Magnification: 10X
(See figure on previous page.)
Fig. 3 a Percentage of wound closure in MDA-MB231 cells after treatments with three different concentrations of flavokawain B. Representative
images of the wound in MDA-MB231 at 0 hourand 24 h upon treatment with flavokawain B. b In vitro matrigel-transwell invasion assay was performed
on MDA-MB231 treated cells after being serum-starved for 24 h. Cells were allowed to invade an extracellular matrix (matrigel) concurrently being
treated with three different doses of flavokawain B. c In vitro transwell migration assay was conducted in MDA-MB231 cells when treated with three
different concentrations of flavokawain B for 24 h. Cells were allowed to migrate through an 8 μM pore with FBS as a chemo-attractant. Magnification:
20X. Data are expressed as mean ± S.E.M. (p < 0.05)
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reported that HSP27 inhibits the in vitro proliferation of
several cancer cells but nonetheless, it also affects the
metastatic phenotype [35]. P38 is also involved in the
regulation of other cell cycle associated proteins such as
p53 and ATF2 [36, 37]. Additionally, it can be seen that
there is a difference in the level of expression of p-CREB.
This protein is the downstream product of the p38, ERK1/
2 and AKT pathways. CREB is responsible for the tran-
scription of several survival-related proteins. The p38
MAPK pathway is also commonly intertwined with the
JNK and ERK pathway. JNK is also a major MAPK family
that is activated upon stress. Downstream of this pathway
is c-Jun, and it is known to inhibit proliferation and in-
duce apoptosis in cancer cells [38, 39]. Both levels of
phosphorylated JNK and c-Jun were increased upon treat-
ment with FKB. Additionally, besides p38 and JNK, the
ERK MAPK pathway was also activated. This pathway is
known to have dual roles back and forth between being
anti-apoptotic and pro-apoptotic [40]. Persistent activa-
tion of the ERK ½ pathway is also known to have signifi-
cant effects on the cell cycle machinery and MMP9, as it
is evident in FKB-treated cells [41]. This eventually led to
the deregulation of NF-KB and COX2 [42]. Moreover, the
level of HSP60 was increased in MDA-MB231 upon treat-
ment with FKB. HSP60 is a heat shock protein involved in
ambiguous pro-apoptotic and pro-survival functions in
cancer cells [43].
Materials and methods
Synthesis of flavokawain B
Flavokawain B used in all experiments was synthesized
by the reaction of 4′,6′-dimethoxy-2′-hydroxyacetophe-
non and benzaldehyde. Acetophenone and aldehyde
were mixed together with 40 % solution of KOH. The
detailed synthesis, purification and characterization of
flavokawain B has already been explained in our previ-
ous publication [34]. The purity of FKB was 99.9 %.
Below is the NMR data obtained after synthesizing FKB:
(Flavokawain B) (E)-1-(2′-Hydroxy-4′,6′-
dimethoxyphenyl)-3-phenylprop-2-en-1-one
(E)-1-(2′-Hydroxy-4′,6′-dimethoxyphenyl)-3-
phenylprop-2-en-1-one: yellow needles crystals: yeild
82.4 %, m.p. 102–104 °C, EI-MS m/z 284.23, (molecular
formula C17H16O4).
1HNMR (CDCl3, 500 MHz). δ 7.92
(d,1H, J =14.5 Hz,Hβ), 7.80 (d,1H, J = 14.5 Hz, Hα),
Fig. 5 Relative mRNA expression level of metastasis-related genes; MMP9, VEGF, GLUT1, NF-KB, CXCR4, MRP1 and FOXM1 in MDA-MB231 cells
48 h post-treatment with three concentrations flavokawain B for 18 h. Experiment was done in triplicates and all data are expressed as mean ±
S.E.M. Protein expression of several metastasis-related proteins; MRP-1, NF-kb, COX-2, VEGF, SNAIL and CXCR4 in MDA-MB231 cells 48 h post-treatment
with three doses of flavokawain B
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Fig. 6 Proteome Profiler TM using Phospo-RTK using MDA-MB231 cell lines treated with flavokawain B for 48 h. Experiment was done in triplicates
and all data are expressed as mean ± S.E.M
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7.62 (br,d, 2H, H-2,6), 7.46 (m, 3H,H-3, 4, 5), 6.12 (br,s,
1H, H-3′), 5.98 (br,s, 1H, H-5′), 3.93 (s, 3H, OMe,
C-6′), 3.85 (s, 3H, OMe, C-4′).
Ethical approval
According to the Universiti Putra Malaysia’s Institutional
Animal Care and Use Committee (IACUC), the usage of
cell lines obtained from a commercial source does not
require an ethical approval from the committee. For the
ex vivo assays, the experiments were done in accordance
to the Institutional Animal Care and Use Committee
guidelines. The ethical approval for the ex vivo study
was sought and obtained from the Universiti Putra
Malaysia’ Institutional Animal Care and Use Committee
(IACUC).
Cell culture
The cell lines MCF-7, MDA-MB231 and MCF-10A were
obtained from the ATCC collection (ATCC, Rockville,
MD, USA). MCF-7 was maintained in RPMI supple-
mented with 10 % fetal bovine serum (FBS), while
MDA-MB231 was maintained in DMEM, supplemented
with 10 % FBS. MCF-10A on the other hand, was main-
tained in DMEM-F12 media supplemented with hydro-
cortisone (0.5 μg/ml), insulin (10 μg/ml), hEGF (20 ng/
ml) and 10 % (v/v) FBS. All the cells were kept in a 37 °
C incubator with 5 % CO2.
MTT assay
This assay was performed as outlined by Mosmann
(1983) [45] with minimal modifications. The cells were
seeded in a 96-well plate at a concentration of 0.8x105
cells/ml. Flavokawain B was added to the wells at the de-
sired concentrations one day after the seeding. After the
designated incubation time, MTT solution (5 mg/ml)
was added at a volume of 20 μl in each well and the cells
were incubated for an additional three hours. Then, the
solution was removed, and 100 μl of DMSO was added
to solubilize the crystals. The plates were then read
using the μquant plate reader at the wavelength of
570 nm (Bio-tek instruments, USA). The following
method of calculation was used to determine the per-
centage of viable cells:
Percentage of Cell Viability
¼ A570Control =A570Sample½  x 100 %
Cell treatment
Based on the MTT assay, subsequent assays were per-
formed according to the results obtained. FKB was dis-
solved in DMSO and the percentage of administration
to the cells was less than 0.1 %. Three different concen-
trations of flavokawain B were used in the treatment of
MCF-7 and MDA-MB231 as outlined in Table 1. The
control sample was treated with the vehicle (DMSO)
at 0.1 %.
BrdU incorporation assay
The BrdU incorporation was measured using the BrdU
Cell Proliferation Kit (Merck, Germany). The cells were
seeded in a 96 well plate at a concentration of 0.8x105
cells/ml and left overnight. The next day, the cells were
treated with three different concentrations of flavoka-
wain B. 24 h before fixing the cells, 20 μl of BrdU was
added to each well. After the respective incubation
hours, the cells were fixed and denatured using a fixing
solution. The plates were then stored at 4 °C. Then, the
plates were washed twice before adding 100 μl of the de-
tector antibody into each well for 1 h. Next, 100 μl of
Goat anti-mouse Ig G-HRP conjugated was added for
30 min. Afterwards, the plates were incubated with
100 μl of the TMB substrate for roughly 30 min. Finally,
100 μl of stop solution was added and the absorbance
was measured at 450 nm, using the μquant plate reader
(Bio-tek Instruments, USA).
Cell cycle analysis
The cells were seeded in 6 well plates at a density of
2.4x105 cells/ml. The following day, the cells were
treated with three different concentrations of flavoka-
wain B. After 12 and 24 h of treatment, the cells were
detached using trypsin, washed with PBS and collected.
The resulting pellet was fixed in 80 % ethanol and stored
at −20 °C. After a week, the fixed cells were washed with
PBS and treated with RNAse and Triton-X 100, and
were then stained with propidium iodide (PI) for 15 min
(Sigma, St Louis, MO, USA). Afterwards, the cells were
subjected to flow cytometric analysis using the FACS
Calibur flow cytometer (Becton Dickinson, USA).
Annexin V/FITC assay
The Annexin V assay was carried out using the Annexin
V Kit (BD Pharmingen, USA). Cells were seeded in 6
well plates (2.4x105 cells/ml) and were treated with the
desired concentrations of flavokawain B. After 24, 48
and 72 h of treatment, the treated cells were collected
and harvested according to the desired time points. The
Table 1 The doses of flavokawain B used in the treatment of
MCF-and MDA-MB231 in all of the assays
Cell line
Flavokawain B (μM) MCF-7 MDA-MB231
IC25 10.5 6
IC50 31.1 12.3
IC75 40.5 24.6
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resulting pellets were immediately resuspended in the
provided binding buffer and subsequently stained with
5 μ lof Annexin V-FITC and 5 μl of PI. The subsequent
mixture was left to incubate at room temperature for
15 min. Afterwards, the cells were analyzed using the
FACS system (Becton Dickinson, Franklin Lakes, NJ,
USA).
Wound healing assay
The cells were seeded in 6 well plates to total confluence
for 24 h. On the day of the treatment, a wound was in-
troduced in the middle of the wells using a sterile yellow
tip pipette. Afterwards, the media was replaced with
fresh media along with the addition of the designated
compounds. The migration of cells was photographed at
10x magnification for every 3 h up until 24 h. The rate
of migration was calculated based on the following
formula.
% Percentage of Wound closure
¼ ðLength of wound at 0 h− nð Þ hð Þ
=Length of wound at 0 hÞ  100
Transwell migration/Invasion assay
The transwell migration/invasion assay was performed
using an 8 μM pore cell culture insert (BD, USA).
Matrigel (BD, USA) was diluted at a ratio of 1:3 with
serum-free media and was applied to the top chamber
of the cell culture inserts for the invasion assay,
whereas in the migration assay, the inserts were not
coated. The matrigel-coated inserts were left for 2 h to
solidify before being used. Next, 2x105 cells/ml were
seeded in the upper chamber of the inserts after being
serum-starved for 24 h. The lower chamber was filled with
media containing 10 % of FBS. The cells were incubated
in a humidified chamber at 37 °C for 24 h. Afterwards, the
non-migrating/invading cells were removed using a cotton
swab. The migrated/invaded cells were fixed in methanol
for 30 min and were stained with crystal violet for 30 min
before being photographed.
HUVEC tube formation assay
This assay was performed as described by Arnaoutova et
al. [46] with slight modifications. Prior to the assay,
50 μl of Matrigel (BD, USA) was seeded in a 96 well
plate for 2 h. HUVEC cells at a density of 1 x105 cells/
ml were seeded in the pre-coated 96 well plates along-
side the treatments. The cells were incubated in a 37 °C-
humidified chamber for 18 h before being photographed
under an inverted light microscope (Nikon, Japan) at
40x magnification.
Rat aortic ring assay
For this experiment, 6-weeks old, male Sprague Drawley
rats were used. Freshly removed aortas were rinsed in
ice-cold PBS supplemented with penicillin-streptomycin
before being cut to 1 mm-1.5 mm segments. The seg-
ments were placed on top of a matrigel-coated 48 well
plate. Another aliquot of 150 μl of ice-cold matrigel was
placed on top of the segments to sandwich it in between
two layers of matrigel, and was allowed to solidify for
2 h at 37 °C. The segments were incubated in ECM
media (Sciencell, USA) for 24 h before being replaced
with fresh ECM media containing three different concen-
trations of Flavokawain B. The aortic rings were photo-
graphed on day 7 using an inverted light microscope
(Nikon, Japan). The Animal Care and Use Committee,
Universiti Putra Malaysia (UPM/FPV/PS/3.2.1.551/AUP-
R168) approved this study according to the guidelines
from the committee.
Quantitative real-time PCR
After the treatment with flavokawain B, total RNA was
isolated using the RNaeasy Kit according to the manu-
facturer’s protocol (Qiagen, Germany). The purity and
concentration of the isolated RNA were measured using
a Nano-spectrophotometer (Beckman Coulter, USA).
Next, 1 μg of the RNA was converted to cDNA using
the QuantiTect Reverse Transcription Kit according to
the manufacturer’s protocol (Qiagen, Hilden, Germany).
Afterwards, real-time PCR was carried out using the
SYBRSelect Master Mix (Invitrogen, USA) on the iCy-
cler IQ5 (Bio-Rad, Hercules, USA). The program for the
PCR reaction was initiated at 95 °C for 10 min. This was
followed by 40 cycles of denaturation at 95 °C for 10 s
and annealing/extension step at 60 °C. Table 2 illustrates
the gene, accession number and sequence of the primers
used. The analysis of the qPCR results were performed
based on the efficiency of the primers using the GeNorm
analysis and two housekeeping genes (GAPDH and
Beta-actin) to normalize. The difference in the fold
change was analysed between the normalized untreated
(control) and FKB-treated samples.
Western blot
Total protein lysates were obtained by lysing the cells
with ice –cold RIPA buffer supplemented with phos-
phatase inhibitor cocktail (Roche, Canada). The quantifi-
cation of protein was measured using the Bradford assay
(Sigma, USA). Next, 100 μg of each sample proteins
were subjected to a 10 % SDS-Page before the proteins
were transferred onto a PVDF membrane (Roche,
Canada) using the Pierce Fast Semi-Dry Blotter (Pierce,
USA). Afterwards, the membranes were blocked in 0.5 %
skimmed milk overnight. The following day, the mem-
branes were washed in TBST for 10 min to a total of 3
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washes and were incubated with the antibodies, anti-
SNAIL (ab82846, Abcam, USA), anti-CXCR4 (ab2074,
Abcam, USA), anti-VEGF (ab1316, Abcam, USA), anti-
COX2 (ab15191, Abcam, USA), anti-NFKB (AHP 1342,
Abdserotec, USA), anti-MRP1(ab32574, Abcam, USA).
Afterwards, the membranes were incubated in the ap-
propriate secondary antibodies conjugated with HRP.
The western blots were then developed under chemilu-
minescence condition (SuperSignal West Pico, Pierce,
USA) using the ChemiDocXRS machine (Bio-rad, USA).
The bands were then analyzed using the Quantity One
1D Analysis software (Bio-rad, USA).
Proteome profiler array TM
The proteome profiler antibody array was employed to
determine the effects of flavokawain B on the phos-
phorylation of several tyrosine kinases. This assay was
done according to the manufacturer’s protocol. The
cell lysates were incubated with the designated mem-
branes overnight at 4 °C. The following day, the mem-
branes were washed three times and were then
incubated with the freshly prepared antibody cocktail
for 2 h. Afterwards, the membranes were washed for
three times again, before being incubated with the
streptavidin-horseradish-peroxidase for 30 min at room
temperature. Then, the membranes were developed under
chemiluminescence conditions using the ChemiDOC XRS
(Bio-rad, USA).
Statistical analysis
All experiments were done in triplicates and the average
values were obtained. The statistical analysis was per-
formed using the GraphPad Prism (version 4.0). For the
experimental analysis the one-way ANOVA was per-
formed followed by Tukey’s post hoc test. The signifi-
cance was set at p < 0.05. The comparison of statistical
significance was done between the control (treated) and
flavokawain B treated groups.
Conclusion
In conclusion, FKB remains a promising anti-cancer agent
in treating breast cancer especially metastatic breast
cancer. It is in our future interest to do further in-depth
study to investigate the effects of FKB on p38 pathway,
NRF-2 pathwa, thioredoxin pathway and other cell stress-
related pathways. Further studies are required to truly
understand the functional machinery of FKB.
Additional files
Additional file 1: Figure S1. Bar chart analysis of the cell cycle assay in
three independent replicates of both MCF-7 and MDA-MB231. All data are
expressed as mean ± S.E.M with three biological replicates. (TIF 103 kb)
Additional file 2: Figure S2. Bar chart analysis of the Annexin V assay
in three independent replicates of both MCF-7 and MDA-MB231 after 24, 48
and 72 h of tretmanet with FKB. All data are expressed as mean ± S.E.M with
three biological replicates. (TIF 94 kb)
Table 2 Sequence, accession number, length of amplicon and the name of the gene of the primers used in the qPCR analysis
Accession number Gene Amplicon length Sequence
NM_001101.3 ACTB 184 F: 5′-AGAGCTACGAGCTGCCTGAC-3′
R: 5′-AGCACTGTGTTGGCGTACAG-3′
NM_002046.4 GAPDH 206 F: 5- GGATTTGGTCGTATTGGGC-3
R: 5- TGGAAGATGGTGATGGGATT-3
NM_001287044.1 VEGF 195 F: 5-GCTGTGGACTTGAGTTGGG-3
R: 5-GCTGGGTTTGTCGGTGTT-3
NM_001243089.1 FOXM1 175 F: 5-ATACGTGGATTGAGGACCACT-3
R: 5-TCCAATGTCAAGTAGCGGTTG −3
NM_006516.2 GLUT1 168 F: 5- ACAACACTGGAGTCATCAATGC −3
R: 5-CCACAGAGAAGGAGCCAATCA-3
NM_004994.2 MMP9 266 F: 5-GAGTGGCAGGGGGAAGATGC-3
R: 5-CCTCAGGGCACTGCAGGATG-3
NM_019898 MRP1 117 F: 5-GTCGGGGCATATTCCTGGC-3
R: 5-CTGAAGACTGAACTCCCTTCCT-3
NM_003998 NF-KB 104 F: 5-AACAGAGAGGATTTCGTTTCCG-3
R: 5-TTTGACCTGAGGGTAAGACTTCT-3
NM_003467 CXCR4 96 F: 5-ACGCCACCAACAGTCAGAG-3
R: 5-AGTCGGGAATAGTCAGCAGGA-3
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AKT: RAC-alpha serine/threonine-protein kinase; ATF-2: activating
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